The patent of belinostat, the only drug for T-cell lymphoma treatment by Wanle pharmaceutical, was approved

The patent "a method to synthesize belinostat" applied by Wanle pharmaceutical, a subsidiary of Guoyao group united Pharmaceutical Co., Ltd., has been issued a patent certificate by the State Intellectual Property Office today It is understood that the price of the patented product on the "Selleck China" website is 1982 yuan per 10 mg dose, and it has been approved by the US Food and Drug Administration (FDA) to enter the fast approval channel, which is still the first in China According to the patent abstract, bellinostat (HDACi) is considered to be a promising anticancer drug target in the future It is the only drug recognized in the international market to treat T-cell lymphoma At the same time, it has a single or combined therapeutic effect on mesothelioma, B-cell lymphoma, AML, soft tissue sarcoma, MDS, liver cancer, colorectal cancer and ovarian cancer In addition, belinostat can not only block the growth of tumor cells, induce tumor cell differentiation and apoptosis, but also has good tolerance and non-toxic response The invention of Wanle pharmaceutical industry provides a method for the synthesis of belinostat The starting material of the method is cheap and easy to obtain, no dangerous reagents are used, and the process is environmentally friendly and suitable for industrial production In recent years, the American Society of Clinical Oncology (ASCO) has repeatedly mentioned the research results of bellinostat at its annual meeting Sppi company (NASDAQ: sppi) is mainly engaged in the research of blood diseases and tumors Recently, the company announced that its phase II clinical trial of belinstat, an HDAC inhibitor, exceeded the expected goal, and claimed that belinstat is its later production line Top important products On December 10 last year, the FDA approved the request of topotarget (NASDAQ: TOPO) to give priority to the examination of the new drug belinostat, which shows that the future market of belinostat will be bright Cancer is the second leading cause of death in the world According to the global cancer report 2014 released by the World Health Organization (who) on February 4, the number of cancer patients and deaths worldwide is increasing uneasily Nearly half of new cancer cases appear in Asia, most of them in China The report also predicts that the global cancer cases will show a rapid growth trend, from 14 million in 2012 to 19 million in 2025, and to 24 million in 2035, of which China will account for 21.9% of the global total In addition, according to market survey data, since 2007, China's anti-tumor drug market has maintained a growth rate of more than 22%, and the market scale in 2013 is close to 100 billion yuan It is reported that Wanle pharmaceutical is one of the first professional manufacturers of anti-tumor drugs in China, and has a series of national key new products, including pirarubicin, adrobicin, doxorubicin, daunorubicin, docetaxel, vincristine, bleomycin, lastest, mesna, ifosfamide, etc The company's products sell well at home and abroad With its outstanding performance in the second comprehensive ranking of national anti-tumor manufacturers, it has become the leader of the industry According to the analysis of the insiders, the approval of the new anti-cancer patent not only means that the anti-tumor product line of Sinopharm and Wanle pharmaceutical industry has been further improved, but also further consolidates the leading position of the anti-cancer drug industry.